Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions

Journal of Nuclear Medicine

Volumn 41, Issue 4, 2000, Pages 682-687

  Bouchet, Lionel G ^b   Bolch, Wesley E ^b   Goddu, S Murty ^b   Howell, Roger W ^b   Rao, Dandamudi V ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Bone pain; Dosimetry; Radionuclide therapy

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; ERBIUM 169; LUTETIUM; PHOSPHORUS; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; SAMARIUM 153; STRONTIUM 89; TIN;

ARTICLE; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; DOSIMETRY; HUMAN; PALLIATIVE THERAPY; PRIORITY JOURNAL;

BONE MARROW; BONE NEOPLASMS; HUMANS; PAIN, INTRACTABLE; PALLIATIVE CARE; PHOSPHORUS RADIOISOTOPES; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; TIN;

EID: 0034110727     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Silberstein EB. The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin Oncol. 1993;20:10-21.
2. Ackery D, Yardley J. Radionuclide-targeted therapy for the management of metastatic bone pain. Semin Oncol. 1993;20(3 suppl 2):27-31.
3. 32P] diphosphonate dose determination in patients with bone metastases from prostatic carcinoma. J Nucl Med. 1978;19:98-104.
4. Holmes RA. Radiopharmaceuticals in clinical trials. Semin Oncol. 1993;20:22-26.
5. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum [B]. 1987;14:223-232.
6. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34:1839-1844.
7. Atkins HL, Mausner LF, Srivastava SC, Meinken GE, Cabahug CJ, D'Alessandro T. Tin-117m(4+)-DTPA for palliation of pain from osseous metastases: a pilot study. J Nucl Med. 1995;36:725-729.
8. Swailem FM, Krishnamurthy GT, Srivastava SC, et al. In-vivo tissue uptake and retention of Sn-117m(4+)DTPA in a human subject with metastatic bone pain and in normal mice. Nucl Med Biol. 1998;25:279-287.
9. Krishnamurthy GT, Swailem FM, Srivastava SC, et al. Tin-117m(4+)DTPA: pharmacokinetics and imaging characteristics in patients with metastatic bone pain. J Nucl Med. 1997;38:230-237.
10. Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculations. Revised ed. New York, NY: The Society of Nuclear Medicine; 1991.
11. Bouchet LG, Bolch WE, Howell RW, Rao DV. S values for radionuclides localized within the skeleton. J Nucl Med. 2000;41:189-212.
12. Bouchet LG, Jokisch WJ, Bolch WE. A three-dimensional transport model for determining absorbed fractions of energy for electrons within trabecular bone. J Nucl Med. 1999;40:1947-1966.
13. Beddoe AH, Darley PJ, Spiers FW. Measurements of trabecular bone structure in man. Phys Med Biol. 1976;21:589-607.
14. Beddoe AH. Measurements of the microscopic structure of cortical bone. Phys Med Biol. 1977;22:298-308.
15. Darley PJ. An Investigation of the Structure of Trabecular Bone in Relation to the Radiation Dosimetry of Bone-Seeking Radionuclides [thesis]. Leeds, UK: University of Leeds; 1972.
16. Whitwell JR. Theoretical Investigations of Energy Loss by Ionizing Particles in Bone [thesis]. Leeds, UK: University of Leeds; 1973.
17. Whitwell JR, Spiers FW. Calculated beta-ray dose factors for trabecular bone. Phys Med Biol 1976;21:16-38.
18. Bielajew AF, Rogers DWO. PRESTA, the "parameter reduced electron step transport algorithm" for electron Monte Carlo transport. Nucl Instr Meth B. 1987;18:165-181.
19. Ford RL, Nelson WR. The EGS Code System: Computer Programs for Monte Carlo Simulation of Electromagnetic Cascade Shower. Report 210, Palo Alto, CA: Stanford Linear Accelerator Center; 1978.
20. Nelson WR, Hirayama RH, Roger DWO. The EGS4 Code System. SLAC-Report-265, Palo Alto, CA: Stanford Linear Accelerator Center; 1985.
21. International Commission on Radiological Protection. Basic Anatomical and Physiological Data for Use in Radiological Protection: The Skeleton. ICRP Publication 70. Tarrytown, NY: Internalional Commission on Radiological Protection; 1995.
22. Lewington VJ. Cancer therapy using bone-seeking isotopes. Phys Med Biol. 1996;41:2027-2042.
23. Snyder WS, Ford MR, Warner GG. Estimates of Specific Absorbed Fractions for Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom. MIRD Pamphlet No. 5, revised. New York, NY: Society of Nuclear Medicine; 1978.
24. Snyder WS, Ford MR, Warner GG, Watson SB. A Tabulation of Dose Equivalent per Microcurie-Day for Source and Target Organs of an Adult for Various Radionucletides. ORNL-5000. Oak Ridge, TN: Oak Ridge National Laboratory; 1974.
25. Samaratunga RC, Thomas SR, Hinnefeld JD, et al. A Monte Carlo simulation model for radiation dose to metastatic skeletal tumor from rhenium-186(Sn)-HEDP. J Nucl Med. 1995;36:336-350.
26. Leblond CP, Wilkinson GW, Belanger LF, Robichon J. Radio-autographic visualization of bone formation in the rat. Am J Anat. 1950;9:289-296.
27. Leblond CP, Wilkinson GW, Belanger LF, Robichon J. Radio-autographic visualization of bone formation in the rat. J NIH Res. 1997;9:44-55.
28. 32P-orthophosphate: implications for therapy of bone pain and bone metastases. J Nucl Med. 2000: in press.
29. Brown E, Firestone RB. Table of Radioactive Isotopes. New York, NY: Wiley; 1986.
30. Weber DA, Eckerman KF, Dillman LT, Ryman JC. MIRD: Radionuclide Data and Decay Schemes. New York, NY: Society of Nuclear Medicine; 1989.
31. International Commission on Radiation Units and Measurements. Stopping Powers for Electrons and Positrons. ICRU Report 37. Bethesda, MD: International Commission on Radiation Units and Measurements; 1984.